Complete360-Care

Complete360.Care AI-Powered Precision Health, Made Understandable Complete360.Care is an AI-driven healthcare portal and connected ecosystem designed to help patients and clinicians truly understand next-generation health data generated by the Complete360® platform. Through the app, users can directly order ultra-deep blood profiling tests—including Complete360® (10,000+ proteins, 700+ metabolites, and 1,400+ lipids)—as well as additional laboratory-developed tests (LDTs) offered by Complete Omics Inc., a leading next-generation molecular diagnostics laboratory. The platform enables longitudinal tracking of results, secure sharing of clinician-ready reports with physicians, and seamless collaboration across care teams. At its core, Complete360.Care combines AI-driven interpretation with one of the world’s most comprehensive and deeply validated blood biomarker datasets, generated by the patented, peer-reviewed Complete360® clinical proteomics platform. By integrating ultra-deep multi-omics patterns with rigorous literature mining, curated biomedical knowledge, and clinical best practices, the app transforms complex molecular signals into clear, medically actionable insights. Complete360.Care summarizes key findings, highlights meaningful trends and deviations over time, and links molecular signals to underlying biological pathways—providing users and clinicians with a deeper, real-time view of individual health. As a connected ecosystem, it further supports clinical decision-making by delivering evidence-based diagnostics, generating practical, literature-grounded insights, and connecting users with relevant local healthcare services to enable informed care and ongoing health management. Intellectual Property Notice Complete360.Care™ and its associated software, systems, methods, and functionalities are protected by intellectual property laws, including issued patents and pending patent applications in the United States and other jurisdictions. This application is covered by U.S. Patent Application Nos. 19/198,934, 19/309,422, and 17/762,425, as well as U.S. Provisional Patent Application Nos. 63/898,368 and 63/898,378. Additional patents and patent applications may be pending. This notice is provided for purposes of intellectual property protection and compliance with applicable patent-marking requirements.